Balazs Gyorffy
Overview
Explore the profile of Balazs Gyorffy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
385
Citations
16104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ocana A, Pandiella A, Privat C, Bravo I, Luengo-Oroz M, Amir E, et al.
Biomark Res
. 2025 Mar;
13(1):45.
PMID: 40087789
Artificial intelligence (AI) can transform drug discovery and early drug development by addressing inefficiencies in traditional methods, which often face high costs, long timelines, and low success rates. In this...
2.
Ungvari Z, Fekete M, Lehoczki A, Munkacsy G, Fekete J, Zabo V, et al.
Geroscience
. 2025 Mar;
PMID: 40072786
The link between abnormal sleep duration and stroke outcomes remains contentious. This meta-analysis quantifies how both short and long sleep durations impact stroke incidence and mortality. A comprehensive search was...
3.
Ungvari Z, Fekete M, Varga P, Fekete J, Lehoczki A, Buda A, et al.
Geroscience
. 2025 Mar;
PMID: 40072785
Sleep duration is a crucial factor influencing health outcomes, yet its relationship with mortality remains debated. In this meta-analysis, we aimed to investigate the association between short and long sleep...
4.
Callari M, Dugo M, Barreca M, Gyorffy B, Galbardi B, Vigano L, et al.
Nat Commun
. 2025 Mar;
16(1):2195.
PMID: 40038334
Improved outcomes in HER2+ female breast cancer have resulted from chemotherapy and anti-HER2 therapies. However, HER2+ER+ cancers exhibit lower response rates. The phase 2 NA-PHER2 trial (NCT02530424) investigated chemo-free preoperative...
5.
Fekete J, Gyorffy B
J Med Internet Res
. 2025 Feb;
27:e64016.
PMID: 39928123
Background: A meta-analysis is a quantitative, formal study design in epidemiology and clinical medicine that systematically integrates and quantitatively synthesizes findings from multiple independent studies. This approach not only enhances...
6.
Muller D, Gyorffy B
Br J Pharmacol
. 2025 Jan;
182(7):1452-1465.
PMID: 39871596
Background And Purpose: Genome-wide methylation studies have significantly advanced our understanding of colorectal adenocarcinoma progression and biomarker discovery. Aberrant DNA methylation plays a crucial role in gene expression regulation during...
7.
Fekete M, Varga P, Ungvari Z, Fekete J, Buda A, Szappanos A, et al.
Geroscience
. 2025 Jan;
PMID: 39797935
Age-related cognitive impairment and dementia pose a significant global health, social, and economic challenge. While Alzheimer's disease (AD) has historically been viewed as the leading cause of dementia, recent evidence...
8.
Ungvari Z, Bartha A, Ungvari A, Fekete M, Bianchini G, Gyorffy B
Geroscience
. 2025 Jan;
PMID: 39777709
Glucagon-like peptide-1 receptor (GLP-1R) agonists, such as exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), albiglutide (Tanzeum), dulaglutide (Trulicity), lixisenatide (Lyxumia, Adlyxin), semaglutide (Ozempic, Rybelsus, Wegovy), and tirzepatide (Mounjaro, Zepbound), are widely...
9.
Ungvari Z, Fekete M, Varga P, Fekete J, Buda A, Szappanos A, et al.
Geroscience
. 2025 Jan;
PMID: 39777701
Stroke is a leading cause of morbidity and mortality worldwide, and dietary patterns have emerged as a significant modifiable factor in stroke prevention. The Mediterranean diet, characterized by high intake...
10.
Pla I, Szabolcs B, Peter P, Ujfaludi Z, Kim Y, Horvatovich P, et al.
Int J Dermatol
. 2024 Dec;
PMID: 39722169
Background: The utilization of PD1 and CTLA4 inhibitors has revolutionized the treatment of malignant melanoma (MM). However, resistance to targeted and immune-checkpoint-based therapies still poses a significant problem. Objective: Here,...